Cancer Drug Mechanisms Group
Currently there are no treatments capable of curing metastatic melanoma and resistance to most treatment options occurs within six months. The complete absence of key transcription factors in a small subpopulation of tumour cells may contribute towards resistance to therapy. This project will investigate the importance of these two transcription factors for response to therapy.
Aim. To determine if dual loss of MITF and BRN2 is responsible for recurrent, therapy resistant, metastatic melanoma.
Approach. This project will require the generation of melanoma cell lines with the inducible removal of both MITF and BRN2. Two and three dimensional growth assays will be utilised to measure drug sensitivities. The project will also determine the downstream targets that lead to therapy resistance with the ultimate goal of designing new treatments to help patients beat melanoma.
- Suitable for Honours or PhD students